FDA Called the Added Vitamin Pretextual: What Templated "Significant Difference" Prescriptions Mean for Florida Prescribers and Telehealth Platforms

If you prescribe compounded semaglutide or tirzepatide through a telehealth platform, and your "significant difference" note reads the same for every patient, FDA has now said in writing what it thinks that note is worth. In a warning letter issued September 18 and posted September 22, 2026, the agency told one of the largest 503A compounding pharmacies in the country that the vitamins it added to its GLP-1 products looked pretextual, and that prescriber determinations repeated verbatim across many records looked pre-generated rather than written for a patient.

The letter went to the pharmacy. The evidence it describes sits in prescriber charts and platform software. That is where the next case starts.

The letter went to the pharmacy. The evidence it describes sits in prescriber charts and platform software.

Key Takeaways

• FDA's September 18, 2026 warning letter treats compounded semaglutide with B12 and tirzepatide with niacinamide as essentially copies, not personalized medicine.
• Under 21 U.S.C. § 353a(b)(2), only a prescriber's patient-specific significant difference determination takes a compounded copy outside the essentially-a-copy bar.
• Identical significant difference statements, pre-loaded as menu options on telehealth platforms, are now named FDA evidence that the determination was never individualized.
• Unapproved drug and misbranding violations under 21 U.S.C. §§ 331 and 333 become felonies with intent to defraud; wire fraud under 18 U.S.C. § 1343 can follow.
• Florida prescribers face a parallel track: Board of Medicine discipline under section 456.072 and Chapter 499 drug charges, alongside Southern District of Florida federal prosecutors.

What FDA Found, and Why Prescribers Should Read It Closely

FDA investigators inspected the Houston pharmacy in November 2025. The letter lists three products by name and strength: two tirzepatide and niacinamide formulations and a semaglutide and cyanocobalamin (vitamin B12) injection. FDA found them to be essentially copies of the approved drugs, compounded regularly and in inordinate amounts, and said the volume suggested the differences from the approved products were pretextual.

The agency relied on three categories of evidence: prescriptions with no significant difference determination at all, prescriptions with determinations "repeated verbatim across many records," and production volume. It then went further. FDA said that generating prescriptions through third-party technology platforms that give prescribers "pre-selected menu options" for a significant difference statement calls the individualized nature of those determinations into question.

FDA named three categories of evidence: no determination at all, determinations repeated verbatim across many records, and production volume. Two of the three live in prescriber charts.

The letter also cites insanitary conditions in sterile production and CGMP failures, including media fill records FDA could not reconcile. Those findings matter to the pharmacy. The significant difference findings matter to everyone who wrote the orders.

The broader enforcement record behind those dates, from the shortage resolutions to the February 2026 escalation, is covered in our analysis of the compounded GLP-1 crisis and federal exposure.

What the Government Is Building

Section 503A exempts a compounded drug from FDA approval, CGMP, and adequate-directions labeling only if its conditions are met. One condition is that a pharmacy not regularly compound essentially copies of a commercially available drug. The statute's escape hatch, 21 U.S.C. § 353a(b)(2), requires a change "made for an identified individual patient" that produces a significant difference "as determined by the prescribing practitioner."

That language puts the prescriber at the center of the legal question. If the determination is real and patient-specific, the product may qualify. If the determination is a checkbox the platform pre-filled, FDA's position is that the product is an unapproved new drug under 21 U.S.C. § 355 and misbranded under 21 U.S.C. § 352(f)(1), and that sterile product made under poor conditions is adulterated under 21 U.S.C. § 351.

In a med spa FDA investigation or a telehealth fraud investigation built on this letter, expect agents to pull three things: the platform's order-entry templates, the prescriber's charts for a sample of patients, and the pharmacy's dispensing volume by prescriber. When a thousand charts carry the same sentence, the government does not need a cooperator to argue the sentence meant nothing.

"Repeated verbatim across many records."— FDA warning letter to a 503A compounding pharmacy, September 18, 2026

Federal and Florida Exposure for Prescribers and Platforms

The core prohibited acts are in 21 U.S.C. § 331: introducing an adulterated, misbranded, or unapproved new drug into interstate commerce. Under 21 U.S.C. § 333(a)(1), a violation is a misdemeanor, and under the responsible corporate officer doctrine from United States v. Park, an executive can be convicted without proof of personal knowledge. With intent to defraud or mislead, section 333(a)(2) makes it a felony carrying up to three years per count.

Prescribers are not immune because the pharmacy compounded the drug. Prosecutors can charge aiding and abetting under 18 U.S.C. § 2, or conspiracy to defraud the United States under 18 U.S.C. § 371 on the theory that templated determinations were designed to keep FDA from treating the product as the copy it was. Telling patients the drug was personalized for them supports wire fraud under 18 U.S.C. § 1343. Where an insurer paid, add health care fraud under 18 U.S.C. § 1347 and false statements relating to health care matters under 18 U.S.C. § 1035.

Prescribers are not immune because the pharmacy compounded the drug. Aiding and abetting, conspiracy, and wire fraud all reach the person who wrote the order.

Florida adds its own track. The Florida Drug and Cosmetic Act, Chapter 499, makes distribution of misbranded drugs a crime, and physicians and advanced practice providers face license discipline under section 456.072. Florida's telehealth statute, section 456.47, holds a telehealth provider to the same standard of care as an in-person visit. A templated note is hard to defend under either. Operators without a Florida license face a separate set of problems, outlined in our post on unlicensed GLP-1 prescribing in Florida.

At sentencing, the misbranding guideline, USSG §2N2.1 in the Guidelines Manual, cross-references to §2B1.1 in fraud cases, and loss then drives the range. For a subscription GLP-1 business, the government will argue that every dollar collected is loss.

Mistakes That Make These Cases Worse

Editing old chart notes. Adding patient-specific reasoning to a closed chart after this letter is the fastest way to turn a regulatory problem into an obstruction count under 18 U.S.C. § 1519.

Relying on the platform. The statute assigns the significant difference determination to the prescriber. A vendor contract does not move that responsibility.

Answering agents or board investigators alone. A friendly conversation about "how the menu works" is an admission about how the menu works.

Assuming a warning letter to someone else means nothing to you. The letter describes prescriber conduct. Prescribers who wrote into that system are fact witnesses, subjects, or both.

A Strategic Defense Approach

Pre-indictment defense here starts with a privileged audit, directed by counsel, of a sample of your own orders: what the significant difference statement says, whether the chart supports it, and how many patients received the same language. That review tells you whether you have a defensible clinical record, a documentation problem you can fix going forward, or exposure you need to address before a prosecutor does.

GLP-1 compounding defense is document work first. A pharmacy preparing its FDA warning letter response will describe its prescribers' role, and a platform will describe its software. Prescribers need their own counsel reading those submissions, because in semaglutide enforcement the next question after the pharmacy is who wrote the orders and who built the menu.

If you are already the subject of a federal investigation, or have received a target letter or subpoena, the decision to proffer, cooperate, or litigate depends on what those records show. Make that decision after the audit, not before. A federal criminal defense attorney should also coordinate any response to the Florida Board of Medicine, because sworn board testimony often reaches the prosecutor's file.

Why Timing Matters Now

Warning letters of this kind are public roadmaps. The prescriber networks behind them are the logical next inquiry, and the general five-year limitations period in 18 U.S.C. § 3282 keeps orders written in 2025 chargeable into 2030.

Charging decisions are still fluid before anyone is indicted. That is when a white collar defense attorney can present context, clinical judgment, and corrective action to the government. After an indictment, the same facts get argued to a jury.

Common Questions

Prescribing Compounded GLP-1s Through a Telehealth Platform in Florida?

If a pharmacy you prescribe through has received a warning letter, or you have been contacted by FDA, the DEA, HHS-OIG, or the Florida Department of Health, speak with counsel before you respond or change any records. AMC Defense Law handles federal investigation defense for prescribers, telehealth platforms, med spas, and compounding pharmacies. The firm's South Florida healthcare fraud defense and Southern District of Florida federal defense work extends to matters nationwide.

Consultations are confidential. Call 561.542.5494.

Consultations are confidential. Call 561.542.5494 or request a confidential consultation.

If you or your loved ones have been arrested or contacted by federal agents over compounded GLP-1 prescribing, call Aaron M. Cohen, 24 hours a day to get help.

This article is for general informational purposes only and is not legal advice. Reading it does not create an attorney-client relationship. Every matter turns on its own facts. The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Prior results do not guarantee a similar outcome.

About the author. Aaron M. Cohen is the founder and principal attorney of AMC Defense Law, a criminal defense firm in Boca Raton, Florida, with more than 30 years of experience in state and federal courts. He is admitted to practice in Florida, New York, New Jersey, and the District of Columbia, and before the United States District Courts for the Southern and Middle Districts of Florida, the Southern, Eastern, and Western Districts of New York, the District of New Jersey, and the Northern District of Texas. He appears pro hac vice in other federal districts nationwide. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.